Lupin Limited has announced the signing of a License and Supply Agreement with Zentiva, k.s., a leading pharmaceutical company based in the Czech Republic, for the commercialization of Lupin’s biosimilar Certolizumab Pegol.

Under the terms of the agreement, Lupin will handle the development, manufacturing, and supply of the biosimilar across agreed territories. Zentiva will take charge of commercialization activities in Europe and CIS countries, leveraging its robust regulatory expertise and commercial infrastructure in the region. Lupin will independently manage commercialization in other markets, including the United States and Canada. The partnership excludes Australia, Japan, Brazil, the Philippines, and India.

As part of the agreement, Zentiva will make a non-refundable payment of up to USD 50 million, which includes an upfront fee of USD 10 million upon execution. Both companies will jointly invest in product development and share profits from the defined markets.

The collaboration does not constitute a related party transaction, and there is no promoter group involvement in Zentiva. The deal aims to strengthen Lupin’s global presence in the biosimilars space and enhance access to affordable, high-quality medicines for patients worldwide.

Zentiva, a prominent pharmaceutical player, serves over 100 million people across more than 30 countries, focusing on affordable healthcare solutions.

Lupin stated that the alliance is expected to boost market reach, accelerate global availability of its biosimilar products, and provide significant value through combined development and commercialization efforts.